These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
591 related articles for article (PubMed ID: 11019976)
1. Desensitization of the platelet aggregation response to ADP: differential down-regulation of the P2Y1 and P2cyc receptors. Baurand A; Eckly A; Bari N; Léon C; Hechler B; Cazenave JP; Gachet C Thromb Haemost; 2000 Sep; 84(3):484-91. PubMed ID: 11019976 [TBL] [Abstract][Full Text] [Related]
2. P2Y1-receptors in human platelets which are pharmacologically distinct from P2Y(ADP)-receptors. Fagura MS; Dainty IA; McKay GD; Kirk IP; Humphries RG; Robertson MJ; Dougall IG; Leff P Br J Pharmacol; 1998 May; 124(1):157-64. PubMed ID: 9630355 [TBL] [Abstract][Full Text] [Related]
3. Activation of the alpha(2A)-adrenoceptor mediates deceleration of the deaggregation component of the response to ADP or 5-HT in human platelets in vitro. Maayani S; Schwarz T; Craddock-Royal B; Tagliente TM Platelets; 2001 Sep; 12(6):359-75. PubMed ID: 11672475 [TBL] [Abstract][Full Text] [Related]
4. Agonist concentration-dependent differential responsivity of a human platelet purinergic receptor: pharmacological and kinetic studies of aggregation, deaggregation and shape change responses mediated by the purinergic P2Y1 receptor in vitro. Maayani S; Schwarz TE; Patel ND; Craddock-Royal BD; Tagliente TM Platelets; 2003; 14(7-8):445-62. PubMed ID: 14713514 [TBL] [Abstract][Full Text] [Related]
5. Ca+2 mobilization and fibrinogen binding of platelets refractory to adenosine diphosphate stimulation. Peerschke EI J Lab Clin Med; 1985 Aug; 106(2):111-22. PubMed ID: 2991399 [TBL] [Abstract][Full Text] [Related]
6. Evidence for two distinct G-protein-coupled ADP receptors mediating platelet activation. Jantzen HM; Gousset L; Bhaskar V; Vincent D; Tai A; Reynolds EE; Conley PB Thromb Haemost; 1999 Jan; 81(1):111-7. PubMed ID: 10348701 [TBL] [Abstract][Full Text] [Related]
7. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice. Léon C; Hechler B; Freund M; Eckly A; Vial C; Ohlmann P; Dierich A; LeMeur M; Cazenave JP; Gachet C J Clin Invest; 1999 Dec; 104(12):1731-7. PubMed ID: 10606627 [TBL] [Abstract][Full Text] [Related]
8. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques. Penz SM; Reininger AJ; Toth O; Deckmyn H; Brandl R; Siess W Thromb Haemost; 2007 Mar; 97(3):435-43. PubMed ID: 17334511 [TBL] [Abstract][Full Text] [Related]
9. Characterisation of species differences in the platelet ADP and thrombin response. Nylander S; Mattsson C; Lindahl TL Thromb Res; 2006; 117(5):543-9. PubMed ID: 15921723 [TBL] [Abstract][Full Text] [Related]
10. Platelet activation by ADP: the role of ADP antagonists. Gachet C Ann Med; 2000 Dec; 32 Suppl 1():15-20. PubMed ID: 11209975 [TBL] [Abstract][Full Text] [Related]
11. ADP induces partial platelet aggregation without shape change and potentiates collagen-induced aggregation in the absence of Galphaq. Ohlmann P; Eckly A; Freund M; Cazenave JP; Offermanns S; Gachet C Blood; 2000 Sep; 96(6):2134-9. PubMed ID: 10979958 [TBL] [Abstract][Full Text] [Related]
12. The P2 receptors in platelet function. Hechler B; Cattaneo M; Gachet C Semin Thromb Hemost; 2005 Apr; 31(2):150-61. PubMed ID: 15852218 [TBL] [Abstract][Full Text] [Related]
14. Differential regulation and relocalization of the platelet P2Y receptors after activation: a way to avoid loss of hemostatic properties? Baurand A; Eckly A; Hechler B; Kauffenstein G; Galzi JL; Cazenave JP; Léon C; Gachet C Mol Pharmacol; 2005 Mar; 67(3):721-33. PubMed ID: 15602005 [TBL] [Abstract][Full Text] [Related]
15. Deaggregation is an integral component of the response of platelets to ADP in vitro: kinetic studies of literature and original data. Maayani S; Tagliente TM; Schwarz T; Craddock-Royal B; Alcala C; Marrero G; Martinez R Platelets; 2001 Aug; 12(5):279-91. PubMed ID: 11487380 [TBL] [Abstract][Full Text] [Related]
16. The P2Y1 receptor is normal in a patient presenting a severe deficiency of ADP-induced platelet aggregation. Léon C; Vial C; Gachet C; Ohlmann P; Hechler B; Cazenave JP; Lecchi A; Cattaneo M Thromb Haemost; 1999 May; 81(5):775-81. PubMed ID: 10365753 [TBL] [Abstract][Full Text] [Related]
17. P2Y12, a new platelet ADP receptor, target of clopidogrel. Herbert JM; Savi P Semin Vasc Med; 2003 May; 3(2):113-22. PubMed ID: 15199474 [TBL] [Abstract][Full Text] [Related]
18. Detection of P2Y(14) protein in platelets and investigation of the role of P2Y(14) in platelet function in comparison with the EP(3) receptor. Dovlatova N; Wijeyeratne YD; Fox SC; Manolopoulos P; Johnson AJ; White AE; Latif ML; Ralevic V; Heptinstall S Thromb Haemost; 2008 Aug; 100(2):261-70. PubMed ID: 18690346 [TBL] [Abstract][Full Text] [Related]
19. Effects of P2Y(1) and P2Y(12) receptor antagonists on ADP-induced shape change of equine platelets: comparison with human platelets. Mateos-Trigos G; Evans RJ; Heath MF Platelets; 2002; 13(5-6):285-92. PubMed ID: 12189014 [TBL] [Abstract][Full Text] [Related]
20. Enhanced increases in cytosolic Ca2+ in ADP-stimulated platelets from patients with delta-storage pool deficiency--a possible indicator of interactions between granule-bound ADP and the membrane ADP receptor. Lages B; Weiss HJ Thromb Haemost; 1997 Feb; 77(2):376-82. PubMed ID: 9157599 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]